Kurt Machemer

Prior to joining the firm, Kurt was an attorney with Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, where his practice focused on representing corporate clients and venture capital firms. He began his legal career at Nutter McClennen & Fish.

• Formation and equity financing of Viridian Therapeutics by Fairmount Funds, Venrock Healthcare Capital Partners, Tellus BioVentures, BVF Partners and others
• Financings of Actithera by M Ventures and Arkin Bio-Holdings
• Acquisition of Proteros biostructures GmbH’s ownership stake in Rodin Therapeutics by Alkermes
• Equity financing of NextPoint Therapeutics by Leaps by Bayer, Sanofi Ventures, MPM Capital Management, Dana-Farber Cancer Institute, Invus, Catalio Capital Management, Sixty Degree Capital and PagodaTree Partners
• Foundation for Angelman Syndrome Therapeutics (FAST) in its venture with Couragene, Inc. to create of CourageAS, Inc.
• Equity financing of Rila Therapeutics
• ONK Therapeutics’ license and collaboration with Intellia to advance allogeneic CRISPR-Edited NK cell therapies
• Praeventix in connection with a private investment by Tellus BioVentures
• Formation and equity financing of Sojournix by RA Capital, Boxer Capital of the Tavistock Group, Frazier Healthcare Partners, Venrock, Janus Henderson Investors and others
• In-license of foundational intellectual property from academia and equity financing of NextPoint Therapeutics by MPM, Binney Street Capital, and Simcere Pharmaceutical
• Co-counsel to Dianthus Therapeutics in its proposed PIPE and concurrent reverse merger with Magenta Therapeutics, Inc. (NASDAQ:MGTA)
• Acquisition by DermBiont of SeylanMed’s lead drug candidate, a topical AKT inhibitor gel
• Co-counsel to Viridian Therapeutics in its reverse merger with miRagen Therapeutics (NASDAQ: MGEN)
• Formation and equity financing of Dianthus Therapeutics by 5AM Ventures, Fidelity Management & Research Company, Venrock Healthcare Capital Partners, Fairmount Funds, Avidity Partners, Wedbush Healthcare Partners, Tellus BioVentures and others
• Foundation for Angelman Syndrome Therapeutics’ (FAST) collaboration with the University of Pennsylvania
• Counseling scientific founders with regard to their advisory board and equity arrangements with ROME Therapeutics
• Equity investment by RA Capital in Vor Biopharma
• Co-counsel to Quellis Biosciences in its reverse merger with Astria Therapeutics, Inc. (NASDAQ:ATXS) (f/k/a Catabasis Pharmaceuticals)
• Acquisition of Siamab Therapeutics’ tumor-associated carbohydrate antigen (TACA) discovery platform by a large commercial-stage biopharmaceutical company
• Financing of GelMedix by HTL Biotechnology and Safar Partners
• Spin out of Otter Immuno-Oncology from the University of Utah
• Equity investment by Merck Research Laboratories in Alector
• Quellis Biosciences’ strategic partnership with Xencor
• Equity investments by Third Rock Ventures in multiple portfolio companies including Blueprint Medicines, Constellation Pharmaceuticals, DC Devices, Edimer Pharmaceuticals, Eleven Biotherapeutics, NinePoint Medical, Nurix, Igenica Biotherapeutics, and Sage Therapeutics
• Acquisition by DermBiont of Chromaderm’s clinical-stage topical inhibitor program
• ProThera Biologics’ strategic partnership with ProMetic Life Sciences
• Equity financing of Claris Biotherapeutics by Novo Ventures and others
• Counseling scientific founder regarding advisory board and equity arrangements with Nuvalent
• Formation and equity financing of Quellis Biosciences by Perceptive Xontogeny Venture Fund and others
• Equity investment by CoVenture in Benitago
• Structured acquisition by Techcomp (Holdings) Limited of IXRF Systems
• Acquisition by DermBiont of BrickBuilt Therapeutics
• Equity investments by 6 Dimensions Capital in multiple portfolio companies, including Hibercell
• Sale of Digital Cognition Technologies’ program that detects pre-symptomatic cognitive impairment to Linus Health
• Spin-out of Versatope Therapeutics from Cornell University
• Formation and equity financing of Keros Therapeutics by Pontifax, Partners Innovation Fund, Arkin Bio Ventures, Medison Pharma and Quark Venture
• Acquisition of Partners Health System’s ownership stake in CoStim by Novartis
• Massachusetts Institute of Technology (MIT) in collaboration with the Skolkovo Foundation to create the Skolkovo Institute of Science and Technology outside Moscow, Russia
• Equity investment by Biogen in Solid GT
• Admission of DermBiont into the Illumina Accelerator program
• Equity financing of Civitas Therapeutics and repayable grant from Michael J. Fox Foundation for Parkinson’s Research
• Option agreement and equity financing of Siamab Therapeutics by Momenta Pharmaceuticals
• Launch by scientific founders of Nocion Therapeutics, including investment from F-Prime, Cannan Partners, Partners Innovation Fund and others
• Strategic equity investment by Biogen in Proteostasis Therapeutics
• Equity investment by Lundbeckfond Ventures in Cydan Development
• Sale of AesRx (with a Phase II sickle cell program) to Baxter International
• Equity investment by Novo A/S in ZS Pharma
• Counseling scientific founders with regard to their advisory board and equity arrangements with Arsenal Therapeutics
• Spin-out and equity financing of Mellitus from Harvard Medical School
• Equity financing of Navitor Pharmaceuticals by Polaris Partners, Atlas Venture, Johnson & Johnson Innovation, S.R. One, Brace Pharma Capital, Remeditex Ventures, Sanofi-Genzyme BioVentures and others
• Acquisition of Codiscope by Synopsys
• Equity investments and flips to U.S.-based topcos by Accel Partners in multiple portfolio companies
• Launch and funding of Vivid Biosciences
• Equity investment by Balderton Capital and Notion Capital in Groupay
• Purchase by Biogen of certain antibody assets from Amgen
• Equity investments by .406 Ventures in multiple portfolio companies, including CloudPercept and Rapid Focus
• Debt and equity investments by Braemar Energy Ventures
• Formation and corporate governance of TransPoC, a not-for-profit scientific research organization
• Equity financing of Foundation Medicine by Google Ventures and Kleiner Perkins Caufield & Byers
• Formation and financing of Unum Therapeutics

Kurt is an active participant in the Big Brothers of Massachusetts Bay mentorship program, a youth sports coach, a member of the Nominating Committee to the Board of Directors at the Winchester Swim & Tennis Club, and a member of the Board of Directors of Pathway to Possible, a 501(c)(3) non-profit organization dedicated to providing housing, support, and advocacy for individuals with cognitive and developmental disabilities. Kurt has previously served as a domestic violence prevention advocate.